Would you prescribe an aromatase inhibitor prophylactically for a post-menopausal woman with a deleterious BRCA2 mutation and a history of DCIS who declines prophylactic mastectomy?

The IBIS II trial (Lancet Onc Forbes et al 2016) established anastrazole was non inferior but not superior in preventing recurrences after DCIS. The MAP3 trial (Goss NEJM) demonstrated efficacy of extemestane vs tamoxifen in the chemoprevention of a first breast cancer in higher risk postmenopausal ...